S6 Ep30: Ramchandren Reviews the Rationale to Further Evaluate CLR 131 in Waldenström Macroglobulinemia
Jan 31, 2022
11:38
forum Ask episode
view_agenda Chapters
auto_awesome Transcript
info_circle Episode notes
Dr Ramchandren discusses current treatment options for patients with Waldenström macroglobulinemia who have limited response to other therapies, the rationale for the expansion cohort of the phase 2 CLOVER-WaM trial evaluating CLR 131 in these patients, and other anticipated research trends in this paradigm.
OncLive® On Air